A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how
well it works compared to induction chemotherapy alone in treating patients with newly
diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase
(ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as
blinatumomab, may block cancer growth in different ways by targeting certain cells. It is not
yet known whether combination chemotherapy is more effective with or without blinatumomab in
treating newly diagnosed acute lymphoblastic leukemia.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.